Retatrutide 40mg x2 Bundle (R&D Only) — 80mg Total
The Retatrutide 40mg x2 Bundle provides two pre-filled research pen injectors delivering 80mg of independently HPLC verified Retatrutide (LY3437943) in total — making it the highest quantity and best value Retatrutide research format available from PeptideCores. Each pen delivers 40mg of triple GLP-1R/GIPR/GCGR receptor co-agonist with precise adjustable click-based dosing of 2.5mg to 10mg per dose. Together the two pens provide up to 32 weekly research doses at 2.5mg or 8 doses at 10mg — sufficient for a full extended research programme. PeptideCores supplies this bundle with a batch-specific Certificate of Analysis from an independent third-party laboratory included on every order. Both pens are supplied from the same independently verified batch ensuring full consistency across the entire research protocol. For laboratory research use only — not for human or veterinary use.
Why Choose the x2 Bundle?
The Retatrutide 40mg x2 Bundle is designed for research programmes requiring the largest available compound quantities at the most cost-effective price per milligram. Researchers conducting extended protocols of 16 weeks or longer at escalating doses from 2.5mg through to 10mg weekly will benefit significantly from having the full 80mg supply secured from a single verified batch — ensuring batch-to-batch consistency across the entire research programme and eliminating the need to re-order mid-protocol from a potentially different batch. Both pens in the bundle are supplied from the same independently verified batch with a single batch-specific COA covering both pens simultaneously. Buying as a bundle also provides a saving compared to purchasing two individual Retatrutide 40mg pens separately.
What is Retatrutide?
Retatrutide (LY3437943) is a synthetic acylated peptide with molecular weight 4759.4 g/mol and molecular formula C210H333N57O65S. It is the first triple GLP-1R/GIPR/GCGR receptor co-agonist to reach Phase 3 research stages and represents the most advanced incretin research compound currently available for laboratory investigation. The 36 amino acid peptide chain incorporates a C20 fatty diacid chain that enables albumin binding in research models, producing an extended duration of receptor activation suited to once-weekly research administration protocols.
Triple Receptor Mechanism of Action
Retatrutide simultaneously activates three pharmacologically distinct receptor systems in research models. GLP-1R agonism drives glucose-dependent insulin secretion from pancreatic beta cells, glucagon suppression from alpha cells, delayed gastric emptying and central appetite suppression via hypothalamic and brainstem GLP-1R expression. GIPR co-agonism adds incretin pathway amplification beyond GLP-1R activation alone, direct effects on adipose tissue lipid metabolism and potentiation of insulin secretion through a complementary intracellular signalling route. GCGR agonism — the defining feature that separates Retatrutide from all previously studied incretin peptides including Semaglutide and Tirzepatide — contributes hepatic glucose output regulation, thermogenic energy expenditure via brown adipose tissue activation, lipolysis in adipose tissue and hepatic fatty acid oxidation. The combination of all three receptor pathways creates a uniquely complex metabolic signalling profile not achievable with any mono or dual agonist.
Research Applications
The Retatrutide 40mg x2 Bundle is suited to extended metabolic biology research programmes studying the integrated effects of triple incretin receptor co-agonism on glucose homeostasis, insulin sensitivity, hepatic lipid metabolism, adipose tissue biology and energy expenditure regulation. The 80mg total quantity provides sufficient compound for comparative receptor engagement studies — using Retatrutide alongside Semaglutide and Tirzepatide to investigate the incremental contribution of each additional receptor target to observed metabolic outcomes across an extended research timeline. Secondary applications include hepatic metabolism programmes investigating GCGR-mediated effects on hepatic glucose output and fatty acid oxidation, and formulation studies evaluating Retatrutide stability across extended pen delivery protocols.
Research Dosing Protocol
The two 40mg pens provide precise adjustable click-based dosing between 2.5mg and 10mg per administration. For extended escalating research protocols the 80mg total supports the following suggested schedule — Weeks 1 to 4 at 2.5mg (10mg consumed), Weeks 5 to 8 at 5mg (20mg consumed), Weeks 9 to 12 at 7.5mg (30mg consumed), Weeks 13 onwards at 10mg using remaining compound. Administer once weekly on the same day each week to maintain consistent research conditions across the full protocol duration. The pen dial displays dose settings clearly at each administration point.
COA and Purity Verification
Every Retatrutide 40mg x2 Bundle is independently HPLC verified at 99%+ purity by an accredited third-party laboratory with no commercial relationship to PeptideCores. The batch-specific Certificate of Analysis included with every bundle covers HPLC chromatogram data confirming purity at 99%+ and mass spectrometry molecular identity confirmation at 4759.4 g/mol for the exact batch contained in both pens. Researchers requiring COA documentation before placing an order can request the current batch certificate via our contact page. For a full explanation of what a research peptide COA should contain see our peptide supplier with COA verification guide.
Product Specifications
Bundle contents — 2 x Retatrutide 40mg R&D research pens
Total quantity — 80mg Retatrutide
Compound — Retatrutide (LY3437943)
Format — 2 x Pre-filled R&D research pen injectors
Dose per click — 2.5mg to 10mg adjustable
Total doses — Up to 32 doses at 2.5mg or 8 doses at 10mg
Receptor targets — GLP-1R / GIPR / GCGR triple agonist
Molecular weight — 4759.4 g/mol
Purity — 99%+ HPLC verified independent third-party
COA — Batch-specific same batch both pens independent laboratory
Research protocol — Once weekly same day each week
Storage — Refrigerated 2 to 8°C do not freeze
Shipping — EU-wide dispatched within 24 hours with cold pack
Storage and Handling
Store both pens refrigerated at 2 to 8°C throughout the research programme — do not freeze. Pre-filled research pens contain the compound in solution and require consistent refrigeration from receipt through to completion of use. Once first administered use each pen within 28 days and keep refrigerated between research administrations. All Retatrutide 40mg x2 Bundle orders are dispatched with cold pack packaging to maintain temperature integrity during transit to European research destinations.
PeptideCores dispatches the Retatrutide 40mg x2 Bundle to all European research destinations — UK, Germany, France, Netherlands, Spain, Italy, Belgium, Austria, Sweden, Denmark, Poland, Greece, Portugal, Ireland and all other EU countries — within 24 hours of order confirmation. Cold pack packaging is included as standard on all pen bundle orders. Full tracking is provided from dispatch through to delivery and all European customer data is handled in strict GDPR compliance. Discreet packaging with no reference to contents on the outer packaging is standard on every shipment.
Disclaimer
This product is intended for laboratory research purposes only. It is not intended for human or veterinary use, diagnosis, treatment or prevention of any condition or disease. Only qualified researchers should handle this compound in appropriate laboratory settings following all relevant safety guidelines and applicable regulations. PeptideCores makes no therapeutic claims regarding this compound.
Reviews
There are no reviews yet.